Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria - Concepedia

Concepedia

Publication | Open Access

Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria

DOI Full Paper Access

73

Citations

18

References

2020

Year

Prajakta Badri, Xuemin Jiang, Anna Borodovsky, Nader Najafian, Jae Kim, Valerie A. Clausen, Varun Goel, Bahru Habtemariam, Gabriel J. Robbie

Clinical Pharmacokinetics

Abstract

NCT02352493.

References

	Year	Citations
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Peter Hillmen, Neal S. Young, Jörg Schubert, New England Journal of Medicine	2006	1.2K
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria Russell P. Rother, Scott A. Rollins, Christopher F. Mojcik, Nature Biotechnology AllergyMedicineDrug DiscoveryHematologyParoxysmal Nocturnal Hemoglobinuria	2007	752
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria Robert A. Brodsky, Neal S. Young, Elisabetta Antonioli, Blood	2007	640
Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria Peter Hillmen, Claire Hall, Judith Marsh, New England Journal of Medicine	2004	631
Genetic Variants in C5 and Poor Response to Eculizumab Jun‐ichi Nishimura, Masaki Yamamoto, Shin Hayashi, New England Journal of Medicine	2014	392
Confidence Interval Criteria for Assessment of Dose Proportionality Brian P. Smith Pharmaceutical Research	2000	348
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates Donald J. Foster, Christopher R. Brown, Sarfraz Shaikh, Molecular Therapy	2018	294
A status report on RNAi therapeutics Akshay Vaishnaw, Jared Gollob, Christina Gamba‐Vitalo, Silence	2010	294
Assessment of Dose Proportionality: Report from the Statisticians in the Pharmaceutical Industry/Pharmacokinetics UK Joint Working Party Kevin Gough, Michael G. Hutchison, Oliver N. Keene, Drug Information Journal Therapeutic Drug MonitoringDose ProportionalityPharmacodynamicsMedicinePharmacometrics	1995	262
Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc–siRNA conjugates Jayaprakash K. Nair, Husain Attarwala, Alfica Sehgal, Nucleic Acids Research Pharmaceutical ScienceMolecular BiologyGene DeliveryMedicinal ChemistryGalnac-sirna Conjugates	2017	258

Page 1